CHUV

Emergex Reports Promising Data from Completed Swiss Phase I Trial of CoronaTcP™, T Cell-Priming Immune Set-Point Candidate for Betacoronaviruses

Retrieved on: 
Wednesday, July 19, 2023
Volunteering, University, Dengue fever, SARS-CoV-2, Lausanne, COVID-19, Infection, RNA, CHUV, University of Lausanne, Gold, Orthornavirae, Peptide, Entrepreneurship, Disease, Safety, Vaccine, Betacoronavirus

Assessment of primary outcome measures of the trial indicate that CoronaTcP showed a favourable safety profile, with no treatment-related serious adverse events observed.

Key Points: 
  • Assessment of primary outcome measures of the trial indicate that CoronaTcP showed a favourable safety profile, with no treatment-related serious adverse events observed.
  • There was no systematic difference between groups that received high or low dose CoronaTcP, in terms of overall safety or reactogenicity.
  • In secondary immunogenicity analyses, the assessment of baseline levels of SARS-CoV-2-specific anti-nucleoprotein antibodies indicated most participants had experienced previous SARS-CoV-2 infection.
  • Professor Thomas Rademacher, Co-Founder and Chief Executive Officer, Emergex, said: “The positive data from both clinical trials – naNO-DENGUE and naNO-COVID - represent an important landmark for Emergex.

RayCare in clinical use with CyberKnife at Lausanne University Hospital (CHUV) in Switzerland

Retrieved on: 
Monday, July 10, 2023
Cyberknife, Partnership, Accuray, RaySearch Laboratories, CHUV, University of Lausanne, FLASH, Patient, Health, Safety, Lausanne University Hospital, Software, Medical imaging, Nursing

STOCKHOLM, July 10, 2023 /PRNewswire/ -- The first treatment - for a patient with brain metastasis - was successfully carried out on June 9.

Key Points: 
  • RaySearch Laboratories AB (publ) announces that Lausanne Univeristy Hospital (CHUV), Switzerland, has treated their first patient using RayStation®* treatment planning system together with the oncology information system RayCare®* in combination with the Accuray CyberKnife® treatment delivery system.
  • Lausanne University Hospital (CHUV) has been a RaySearch customer since 2017.
  • At the same time the hospital also decided to invest in RayCare and RaySearch's oncology analytics system RayIntelligence.
  • Taking RayCare in clinical use with CyberKnife is an important step forward in this program.

Lausanne University Hospital (CHUV) Anesthesiology Department Adopts Masimo W1™ for Use in Preoperative Patient Assessment

Retrieved on: 
Thursday, June 8, 2023
Biometrics, Surgery, Health, Medical Devices, Hospitals, Health Technology, Wearables, Mobile Technology, Technology, Airway management, Anesthesiology, Multimedia, Mentorship, CHUV, Anesthesia, MASI, Vital signs, Patient, Lausanne University Hospital, FDA, Behavior, Safety, Nursing, Masimo

Masimo (NASDAQ: MASI) today announced that the Department of Anesthesiology at the Lausanne University Hospital (CHUV) , one of Switzerland’s premier academic institutions, has chosen to make the Masimo W1™ advanced health tracking watch a key part of its pre-surgical patient assessment research program.

Key Points: 
  • Masimo (NASDAQ: MASI) today announced that the Department of Anesthesiology at the Lausanne University Hospital (CHUV) , one of Switzerland’s premier academic institutions, has chosen to make the Masimo W1™ advanced health tracking watch a key part of its pre-surgical patient assessment research program.
  • Masimo W1, which offers accurate, continuous measurements of key physiological parameters, is available in Europe as a medical device that integrates with the Masimo SafetyNet® remote patient management platform.
  • The baseline data can then allow clinicians to know what is normal and abnormal for each patient they care for in the hospital.
  • Also, with Masimo W1, they can remotely monitor the patient post surgery at home when appropriate and reduce how long the patient remains in the hospital.

Brain Computer Interface (BCI) Enables Thought-Controlled Walking after Spinal Cord Injury

Retrieved on: 
Wednesday, May 24, 2023
Medical device, Spinal cord stimulator, BCI, ARC, Movement, CHUV, Paralysis, CEA-Leti: Laboratoire d'électronique des technologies de l'information, Euronext, Research, EPFL, SCI, Safety, Lausanne University Hospital, Nature

EINDHOVEN, the Netherlands, May 24, 2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces a publication in Nature showing that a wireless brain-computer interface (BCI) can use thought to modulate ARC Therapy.

Key Points: 
  • EINDHOVEN, the Netherlands, May 24, 2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces a publication in Nature showing that a wireless brain-computer interface (BCI) can use thought to modulate ARC Therapy.
  • Researchers reported that when paired with ARC Therapy, an implanted BCI allowed an individual to gain augmented control over when and how he moved his paralyzed legs.
  • “I look forward to working with the ONWARD team to advance this important new technology.”
    The data published today are part of an ongoing clinical feasibility study investigating the safety and preliminary effectiveness of brain-controlled spinal cord stimulation after SCI.
  • All ONWARD devices and therapies, including but not limited to ARC-IM, ARC-EX, and ARC Therapy, are investigational and not available for commercial use.

ONWARD Announces First-in-Human Use of ARC-IM™ Lead to Restore Movement and Function after Spinal Cord Injury

Retrieved on: 
Monday, May 15, 2023
Blood pressure, Lead, Swiss, IPG, University, University of Calgary, Lausanne, Spinal cord, ARC, Quality of life, Research, CHUV, Movement, Euronext, Patient, EPFL, SCI, FDA, Swiss Federal Institute of Aquatic Science and Technology, Pharmaceutical industry, Medical device, Nature, MD

EINDHOVEN, the Netherlands, May 15, 2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announced the successful first-in-human use of its investigational ARC-IM Lead.

Key Points: 
  • EINDHOVEN, the Netherlands, May 15, 2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announced the successful first-in-human use of its investigational ARC-IM Lead.
  • The ARC-IM Lead delivers targeted electrical pulses to the spinal cord and is a key component of the ONWARD ARC-IM system, an innovative platform engineered to deliver ARC Therapy to address multiple indications.
  • The ARC-IM Lead is designed to be used with the ARC-IM neurostimulator (IPG) and is purpose-built for placement along the spinal cord to stimulate the dorsal roots, with specific parameters designed for each anatomical location.
  • “The purpose-designed ARC-IM Lead will unlock our ability to optimally deliver ARC Therapy to address many of the challenges faced by people with spinal cord injury,” said Dave Marver, CEO of ONWARD.

IntraOp Announces First Randomized Phase II Selection Trial of FLASH Versus Conventional Radiotherapy for Patients with Localized Carcinomas

Retrieved on: 
Friday, May 12, 2023
Oncology, Health, Medical Devices, Radiology, Clinical Trials, Research, Science, Electron, University, Intraoperative electron radiation therapy, Therapeutic index, Toxicity, Medicine, SOC, Radiation therapy, Sale, CHUV, University of Lausanne, Teaching hospital, US, Radiation, LINAC, FLASH, Patient, Standard of care, NMSC, Safety, Lausanne University Hospital, Pharmaceutical industry, Medical imaging, Dermatology

It marks the first time a randomized trial will compare FLASH radiotherapy* to conventional radiotherapy in treating nonmelanoma skin cancer (NMSC).

Key Points: 
  • It marks the first time a randomized trial will compare FLASH radiotherapy* to conventional radiotherapy in treating nonmelanoma skin cancer (NMSC).
  • It is the second clinical human trial to use the IntraOp® Mobetron® electron-based linear accelerator (LINAC).
  • “This feels like a breakthrough moment in our collective study of the role and effectiveness of FLASH radiotherapy as compared to standard of care radiotherapy.
  • *Ultra-High Dose Rate (UHDR) functionality for FLASH Radiotherapy is for investigational use only and is not cleared for sale by the US FDA.

IntraOp Medical Corporation Announces Their 10th Mobetron with FLASH-IQ Installation Worldwide

Retrieved on: 
Thursday, May 11, 2023
Radiology, Biotechnology, Oncology, General Health, Health, Medical Devices, Hospitals, Health Technology, University, Intraoperative electron radiation therapy, CHUM, Cancer, Research, University of Wisconsin Carbone Cancer Center, Sale, CHUV, University of Lausanne, MD Anderson Cancer Center, Radiation therapy, Radiation, FLASH, Patient, NMSC, Ultra, Growth, Ides, Lausanne University Hospital, Pharmaceutical industry, Nightclub

IntraOp Medical Corporation proudly announces that its IntraOp® Mobetron® with FLASH-IQ™ technology will soon be installed in its tenth institution worldwide, marking a significant milestone in the study of FLASH radiotherapy.

Key Points: 
  • IntraOp Medical Corporation proudly announces that its IntraOp® Mobetron® with FLASH-IQ™ technology will soon be installed in its tenth institution worldwide, marking a significant milestone in the study of FLASH radiotherapy.
  • IntraOp Mobetron with FLASH-IQ is a novel radiotherapy platform capable of delivering an Ultra-High Dose Rate (UHDR) electron beam.
  • Several additional sites are applying for IDEs in the US, along with Canada, Belgium and Germany applying for similar exemptions in their countries.
  • IntraOp supports these applications and looks forward to the continued growth and development in the study of FLASH radiotherapy.

Domo Health partners with Swiss energy leader to bring advanced digital health solutions at home

Retrieved on: 
Wednesday, May 3, 2023
Partnership, Heart failure, Telecommunications, ISO, Roche, Hirslanden, SAK, CHUV, Acquisition, Single-family, Patient, Conditional sentence, Digital, ST, CHF, Environment, Safety, Nursing, Medical device

Together, Domo Health and SAK will expand an offer promoting digital health in private households.

Key Points: 
  • Together, Domo Health and SAK will expand an offer promoting digital health in private households.
  • In addition, Domo Health has announced the launch of its digital health platform domo.health, aimed at revolutionising the coordination of care and optimisation of resources.
  • With a comprehensive digital health approach, Domo Health grew its reputation in the healthcare sector by working with renowned partners such as the CHUV, Hirslanden Group, Inselspital Bern and Roche.
  • Their goal is to provide scalable and sustainable solutions through the use of its digital health AI-assisted platform.

Domo Health partners with Swiss energy leader to bring advanced digital health solutions at home

Retrieved on: 
Wednesday, May 3, 2023
Partnership, Heart failure, Telecommunications, ISO, Roche, Hirslanden, SAK, CHUV, Acquisition, Single-family, Patient, Conditional sentence, Digital, ST, CHF, Environment, Safety, Nursing, Medical device

Together, Domo Health and SAK will expand an offer promoting digital health in private households.

Key Points: 
  • Together, Domo Health and SAK will expand an offer promoting digital health in private households.
  • In addition, Domo Health has announced the launch of its digital health platform domo.health, aimed at revolutionising the coordination of care and optimisation of resources.
  • With a comprehensive digital health approach, Domo Health grew its reputation in the healthcare sector by working with renowned partners such as the CHUV, Hirslanden Group, Inselspital Bern and Roche.
  • Their goal is to provide scalable and sustainable solutions through the use of its digital health AI-assisted platform.

LinKinVax Introduces its Scientific Advisory Board with the Appointment of Three Leading Experts in Immunology and Epidemiology

Retrieved on: 
Wednesday, April 26, 2023
Biotechnology, Other Health, Health, Pharmaceutical, Biometrics, Oncology, Other Science, Research, Infectious Diseases, Science, Clinical Trials, Vaccine, Immunization, Male, Hepatitis, International, Female, University, Journal of the International AIDS Society, HIV, Infection, COVID-19, DC, ANRS, Coronavirus Scientific Advisory Board, Woman, H. Lee Moffitt Cancer Center & Research Institute, Lausanne University Hospital, Doctor of Philosophy, Doherty Institute, CHUV, VRI, HIV Vaccine Trials Network, Cervical cancer, Patient, Helmholtz Centre for Infection Research, HIV/AIDS, HPV, Entrepreneurship, HVTN, Research institute, Immunology, Australian Academy of Health and Medical Sciences, Epidemiology, Laboratory, FRACP, Medicine, Cancer, Immunity

LinKinVax, a clinical-stage biotechnology company, announces the creation of its Scientific Advisory Board with the appointment of three experts in immunology and epidemiology.

Key Points: 
  • LinKinVax, a clinical-stage biotechnology company, announces the creation of its Scientific Advisory Board with the appointment of three experts in immunology and epidemiology.
  • “We are delighted to welcome Prof. Anna Giuliano, Prof. Sharon Lewin and Prof. Giuseppe Pantaleo to our Scientific Advisory Board.
  • “We are very pleased to have convinced these leading experts to join our scientific committee.
  • Their skills and experience in immunology and epidemiology will help guide and optimise all aspects of our clinical development plans for our DC-targeting vaccine platform.